Table 3.

Clinicopathologic features of cohort 2

CharacteristicCLS-B negative (n = 75)CLS-B positive (n = 52)P
Age (years)
 Median (range)44 (32–78)54 (35–84)<0.001
Race, n (%)
 White66 (88%)40 (77%)
 Black7 (9%)10 (19%)
 Asian2 (3%)2 (4%)0.19
BMI
 Median (range)25.3 (17.6–45.3)30.1 (19.9–50.9)<0.001
BMI category, n (%)
 Normal or underweight33 (44%)10 (19%)
 Overweight29 (39%)14 (27%)
 Obese13 (17%)28 (54%)<0.001
Menopausal status, n (%)
 Pre47 (63%)18 (35%)
 Post28 (37%)34 (65%)0.002
Dyslipidemia, n (%)
 No68 (91%)40 (77%)
 Yes7 (9%)12 (23%)0.04
Hypertension, n (%)
 No63 (84%)34 (65%)
 Yes12 (16%)18 (35%)0.02
Diabetes mellitus, n (%)
 No73 (97%)42 (81%)
 Yes2 (3%)10 (19%)0.003
T size, n (%)
 ≤2 cm25 (33%)17 (33%)
 >2–5 cm25 (33%)21 (40%)
 >5 cm25 (33%)14 (27%)0.65
Lymph node status, n (%)
 N011 (15%)20 (38%)
 N+64 (85%)32 (62%)0.003
Tumor receptor status, n (%)
 ER+/HER243 (57%)30 (58%)
 HER2+12 (16%)11 (21%)
 Triple negative20 (27%)11 (21%)0.66
Grade, n (%)
 10 (0%)1 (2%)
 210 (14%)6 (12%)
 359 (86%)44 (86%)0.58
 Missing6 (8%)1 (2%)0.24
Histology, n (%)
 Ductal64 (85%)46 (88%)
 Lobular8 (11%)2 (4%)
 Mixed3 (4%)4 (8%)0.30
Adjuvant radiotherapy, n (%)
 No22 (29%)23 (44%)
 Yes53 (71%)29 (56%)0.093
Adjuvant chemotherapy, n (%)
 No8 (11%)17 (33%)
 Yes67 (89%)35 (67%)0.003
Adjuvant anti-HER2 therapy, n (%)
 No69 (92%)49 (94%)
 Yes6 (8%)3 (6%)0.736
Adjuvant aromatase inhibitor or tamoxifen, n (%)
 No30 (40%)21 (40%)
 Yes45 (60%)31 (60%)1.00
  • Abbreviations: ER, estrogen receptor; PR, progesterone receptor.